We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Continuing its string of proposed buyouts in the rare disease arena, Shire Pharmaceuticals is looking to snap up Massachusetts biotech Dyax in a deal worth up to $6.5 billion. Read More
The senators are asking the FTC to investigate whether the suppliers are taking advantage of the shortage in ways that run afoul of antitrust laws. Read More
Pharmaceutical industry watchers are saying that the Warner Chilcott kickback scandal may not single-handedly reshape the drug promotional landscape … but it’ll make one helluva dent. Read More
Hospira is voluntarily recalling more than 24,000 syringes of the injectable Amidate because out-of-specification results for degraded product were confirmed during stability testing. Read More
The FDA will not be forced into a shutdown this year after the Senate passed a two-year budget early Friday morning for fiscal years 2016 and 2017. Read More
To defuse a growing scandal, Valeant Pharmaceuticals has cut ties with a mail-order pharmacy accused of pushing expensive drugs on pharmaceutical buyers. Read More